Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

P&G To Cut Portfolio In Half, Refocus On Core In Simplification Strategy

This article was originally published in The Tan Sheet

Executive Summary

P&G will divest or discontinue half its brands and focus on lines that account for 90% of its total sales under a streamlining effort CEO A.G. Lafley says will result in portfolio offering “consumer-preferred and customer supported” products.

You may also be interested in...



'Slow-Growth' Global Trend Shakes Up P&G Product Strategy Start To Finish

P&G’s health care segment advanced 4% in the third quarter to $1.84bn, but sales declined for its other business units, a trend the firm sees worldwide across consumer industries. CFO Jon Moeller unveils the firm’s “irresistible superiority” product development strategy to counter slower global consumer spending.

'Slow-Growth' Global Trend Shakes Up P&G Product Strategy Start To Finish

P&G’s health care segment advanced 4% in the third quarter to $1.84bn, but sales declined for its other business units, a trend the firm sees worldwide across consumer industries. CFO Jon Moeller unveils the firm’s “irresistible superiority” product development strategy to counter slower global consumer spending.

P&G Health Care Outshines Other Segments In Q2

The Procter & Gamble Company reported that its health care segment advanced 5% (7% organically) on the strength of innovations in oral care and personal health. The firm’s organic sales increase of 2% in the quarter surpassed analyst expectations.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS107068

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel